liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Chronomodulated capecitabine in combination with short-time oxaliplatin: A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Department of Oncology, Rogaland Central Hospital, Stavanger, Norway.
Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala University Hospital, Uppsala, Sweden.
Show others and affiliations
2008 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 19, no 6, 1154-1159 p.Article in journal (Refereed) Published
Abstract [en]

Background: Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy. Patients and methods: A phase II study examining chronomodulated XELOX30 (XELOX30chron): oxaliplatin: 130 mg/m2 on day 1, as a 30-min infusion between 1 and 3 p.m. Capecitabine: total daily dose of 2000 mg/m2, 20% of the dose between 7 and 9 a.m. and 80% of the dose between 6 and 8 p.m. in patients with mCRC resistant to irinotecan. Seventy-one patients were enrolled. Response rate was 18%, median progression-free survival 5.1 months and median overall survival (OS) 10.2 months. Platelet count and performance status were significantly correlated to OS in multivariate analyses. Neurotoxicity grade 2 and 3 was seen in 25% and 2% of patients, respectively, other grade 3 toxic effects were as follows: nausea 6%, vomiting 3%, diarrhoea 12% (3% experienced grade 4) and palmoplantart erytem 9%. Conclusion: XELOX30chron is a convenient second-line regimen with efficacy and safety profile similar to other oxaliplatin schedules. To further investigate chronomodulated XELOX, we have started a Nordic randomised phase II study comparing XELOX30 and XELOX30chron as first-line therapy in patients with mCRC. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Place, publisher, year, edition, pages
2008. Vol. 19, no 6, 1154-1159 p.
Keyword [en]
Capecitabine, Chronotherapy, Metastatic colorectal cancer, Oxaliplatin, Short-time infusion, XELOX
National Category
Natural Sciences
URN: urn:nbn:se:liu:diva-48765DOI: 10.1093/annonc/mdn002OAI: diva2:269661
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2010-05-24

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Starkhammar, Hans
By organisation
Oncology Faculty of Health SciencesDepartment of Oncology UHL
In the same journal
Annals of Oncology
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 7 hits
ReferencesLink to record
Permanent link

Direct link